Payment overview · 2025
General Payments
$978.17
38 reported records · 13 companies
Healthcare provider profile · identity verified
David Tavdy, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FOREST HILLS, NY · NPI 1710936232
Verified facts
What the public records show
CMS Open Payments records show David Tavdy, MD received $978.17 in general payments during 2025 across 38 reported records.
Novo Nordisk Inc accounted for 17.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rybelsus, Xifaxan, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 334 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 330 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 330 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 298 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 231 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Rybelsus by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulance by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $166.94 | 17.1% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $153.73 | 15.7% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $110.79 | 11.3% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $94.95 | 9.7% | 4 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $90.87 | 9.3% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $89.19 | 9.1% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $64.86 | 6.6% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $56.35 | 5.8% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $45.03 | 4.6% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $33.91 | 3.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $27.72 | 2.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.06 | 2.3% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $21.77 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $978.17 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $166.94 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $153.73 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $110.79 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $94.95 | 4 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $90.87 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $89.19 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $77.87 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $64.86 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $56.35 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $45.03 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $33.91 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $27.72 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $26.43 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.35 | 1 | 2025 |
Source payment records
|
|||||
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $22.06 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $21.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 330 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 298 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 231 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 100 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 114 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
51 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
197 | 39 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
334 | 39 |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
114 | 14 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
29 | 18 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
62 | 16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
330 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
330 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
298 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
89 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
231 | 48 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
100 | 20 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1460 | 275 |
| Amlodipine Besylate | Amlodipine Besylate | 1233 | 213 |
| Eliquis | Apixaban | 825 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 775 | 129 |
| Furosemide | Furosemide | 696 | 123 |
| Gabapentin | Gabapentin | 674 | 121 |
| Losartan Potassium | Losartan Potassium | 674 | 115 |
| Mirtazapine | Mirtazapine | 625 | 87 |
| Tamsulosin Hcl | Tamsulosin Hcl | 607 | 112 |
| Metformin Hcl | Metformin Hcl | 575 | 132 |
| Metoprolol Tartrate | Metoprolol Tartrate | 559 | 89 |
| Famotidine | Famotidine | 522 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 461 | 101 |
| Escitalopram Oxalate | Escitalopram Oxalate | 425 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 411 | 79 |
| Diclofenac Sodium | Diclofenac Sodium | 344 | 56 |
| Synthroid | Levothyroxine Sodium | 334 | 39 |
| Jardiance | Empagliflozin | 330 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 315 | 66 |
| Simvastatin | Simvastatin | 306 | 58 |
| Pantoprazole Sodium | Pantoprazole Sodium | 304 | 101 |
| Mounjaro | Tirzepatide | 298 | 41 |
| Hydralazine Hcl | Hydralazine Hcl | 290 | 48 |
| Carvedilol | Carvedilol | 282 | 42 |
| Donepezil Hcl | Donepezil Hcl | 268 | 45 |
| Finasteride | Finasteride | 261 | 45 |
| Omeprazole | Omeprazole | 259 | 62 |
| Memantine Hcl | Memantine Hcl | 235 | 33 |
| Ozempic | Semaglutide | 231 | 48 |
| Lisinopril | Lisinopril | 230 | 47 |
| Januvia | Sitagliptin Phosphate | 228 | 30 |
| Levetiracetam | Levetiracetam | 226 | 31 |
| Sertraline Hcl | Sertraline Hcl | 224 | 34 |
| Metformin Hcl Er | Metformin Hcl | 216 | 36 |
| Linzess | Linaclotide | 197 | 39 |
| Trazodone Hcl | Trazodone Hcl | 195 | 31 |
| Alprazolam | Alprazolam | 192 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 185 | 17 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 177 | 40 |
| Quetiapine Fumarate | Quetiapine Fumarate | 176 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 174 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 174 | 46 |
| Lactulose | Lactulose | 167 | 17 |
| Potassium Chloride | Potassium Chloride | 167 | 37 |
| Vascepa | Icosapent Ethyl | 166 | 23 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 164 | 23 |
| Enalapril Maleate | Enalapril Maleate | 163 | 17 |
| Risperidone | Risperidone | 147 | 16 |
| Allopurinol | Allopurinol | 144 | 26 |
| Baclofen | Baclofen | 138 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 137 | 19 |
| Divalproex Sodium | Divalproex Sodium | 133 | 16 |
| Glimepiride | Glimepiride | 132 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 132 | 30 |
| Latanoprost | Latanoprost | 130 | 34 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 126 | 22 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 119 | 26 |
| Glipizide | Glipizide | 114 | 25 |
| Zenpep | Lipase/Protease/Amylase | 114 | 14 |
| Montelukast Sodium | Montelukast Sodium | 113 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 112 | 22 |
| Nifedipine Er | Nifedipine | 112 | 16 |
| Ketoconazole | Ketoconazole | 111 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 110 | 47 |
| Spironolactone | Spironolactone | 110 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 102 | 18 |
| Rybelsus | Semaglutide | 100 | 20 |
| Xarelto | Rivaroxaban | 100 | 25 |
| Hydrocortisone | Hydrocortisone | 99 | 35 |
| Buspirone Hcl | Buspirone Hcl | 98 | 13 |
| Farxiga | Dapagliflozin Propanediol | 94 | 23 |
| Meclizine Hcl | Meclizine Hcl | 93 | 36 |
| Mupirocin | Mupirocin | 91 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 32 |
| Trulicity | Dulaglutide | 89 | 19 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 88 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 87 | 31 |
| Sodium Chloride | 0.9 % Sodium Chloride | 87 | 40 |
| Alcohol Pads | Alcohol Antiseptic Pads | 86 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 86 | suppressed |
| Nexium | Esomeprazole Magnesium | 86 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 83 | 23 |
| Amiodarone Hcl | Amiodarone Hcl | 82 | 15 |
| Atenolol | Atenolol | 79 | 16 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 78 | suppressed |
| Ezetimibe | Ezetimibe | 77 | 19 |
| Dexlansoprazole Dr | Dexlansoprazole | 76 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 74 | 17 |
| Humalog Kwikpen U-100 | Insulin Lispro | 74 | 23 |
| Tradjenta | Linagliptin | 74 | 13 |
| Ammonium Lactate | Ammonium Lactate | 73 | 34 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 72 | 18 |
| Nystatin | Nystatin | 72 | 36 |
| Restasis | Cyclosporine | 71 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 70 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 70 | 17 |
| Alendronate Sodium | Alendronate Sodium | 69 | 23 |
| Clonidine Hcl | Clonidine Hcl | 69 | 17 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 68 | 20 |
| Single Use Swab | Alcohol Antiseptic Pads | 68 | 26 |
| Aripiprazole | Aripiprazole | 67 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 66 | 17 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 66 | 16 |
| Amantadine | Amantadine Hcl | 65 | suppressed |
| Myrbetriq | Mirabegron | 62 | 16 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 62 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 59 | 53 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 59 | 20 |
| Novolog Flexpen | Insulin Aspart | 59 | 19 |
| Lamotrigine | Lamotrigine | 58 | suppressed |
| Ranolazine Er | Ranolazine | 58 | 15 |
| Labetalol Hcl | Labetalol Hcl | 57 | 15 |
| Albuterol Sulfate | Albuterol Sulfate | 54 | 16 |
| Azithromycin | Azithromycin | 54 | 43 |
| Entresto | Sacubitril/Valsartan | 54 | 12 |
| Folic Acid | Folic Acid | 54 | 15 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 54 | 19 |
| Santyl | Collagenase Clostridium Hist. | 54 | 20 |
| Clonazepam | Clonazepam | 52 | 13 |
| Incruse Ellipta | Umeclidinium Bromide | 52 | suppressed |
| Creon | Lipase/Protease/Amylase | 51 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 51 | 13 |
| Retacrit | Epoetin Alfa-Epbx | 50 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 49 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 21 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 48 | suppressed |
| Lidocaine | Lidocaine | 47 | 13 |
| Ibandronate Sodium | Ibandronate Sodium | 46 | 11 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 46 | suppressed |
| Valsartan | Valsartan | 46 | suppressed |
| Dexilant | Dexlansoprazole | 45 | suppressed |
| Dihydroergotamine Mesylate | Dihydroergotamine Mesylate | 45 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 45 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | 15 |
| Fluconazole | Fluconazole | 43 | 24 |
| Methimazole | Methimazole | 43 | 13 |
| Midodrine Hcl | Midodrine Hcl | 43 | 15 |
| Admelog Solostar | Insulin Lispro | 42 | 14 |
| Bethanechol Chloride | Bethanechol Chloride | 41 | suppressed |
| Bumetanide | Bumetanide | 41 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 41 | suppressed |
| Prednisone | Prednisone | 41 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 15 |
| Levofloxacin | Levofloxacin | 40 | 35 |
| Torsemide | Torsemide | 40 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 39 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 39 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 39 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 39 | 15 |
| Vancomycin Hcl | Vancomycin Hcl | 39 | 16 |
| Ceftriaxone | Ceftriaxone Sodium | 37 | 30 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 37 | 14 |
| Nystop | Nystatin | 37 | 12 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 36 | suppressed |
| Entacapone | Entacapone | 36 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 36 | suppressed |
| Procto-Med Hc | Hydrocortisone | 36 | suppressed |
| Olanzapine | Olanzapine | 35 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 34 | 12 |
| Silodosin | Silodosin | 34 | suppressed |
| Methocarbamol | Methocarbamol | 33 | suppressed |
| Thiothixene | Thiothixene | 33 | suppressed |
| Dutasteride | Dutasteride | 32 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 32 | suppressed |
| Lorazepam | Lorazepam | 32 | suppressed |
| Procrit | Epoetin Alfa | 32 | suppressed |
| Atovaquone | Atovaquone | 31 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 31 | 14 |
| Loperamide | Loperamide Hcl | 31 | 18 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 30 | suppressed |
| Clemastine Fumarate | Clemastine Fumarate | 30 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 30 | suppressed |
| Ibuprofen | Ibuprofen | 30 | 23 |
| Nateglinide | Nateglinide | 30 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 30 | 21 |
| Repatha Sureclick | Evolocumab | 30 | suppressed |
| Calcitriol | Calcitriol | 29 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | 11 |
| Multaq | Dronedarone Hcl | 29 | suppressed |
| Prolia | Denosumab | 29 | 18 |
| Rivastigmine | Rivastigmine Tartrate | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 28 | 12 |
| Levemir Flexpen | Insulin Detemir | 28 | suppressed |
| Xifaxan | Rifaximin | 28 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 27 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 27 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 11 |
| Combigan | Brimonidine Tartrate/Timolol | 27 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Eszopiclone | Eszopiclone | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 27 | 24 |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Sulfasalazine | Sulfasalazine | 27 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 26 | suppressed |
| Ssd | Silver Sulfadiazine | 26 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 20 |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 25 | 19 |
| Methenamine Hippurate | Methenamine Hippurate | 25 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 25 | 11 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 24 | suppressed |
| Daptomycin | Daptomycin | 24 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 24 | suppressed |
| Levocarnitine | Levocarnitine (With Sugar) | 24 | suppressed |
| Lumigan | Bimatoprost | 24 | suppressed |
| Mupirocin | Mupirocin Calcium | 24 | suppressed |
| Securesafe Pen Needle | Pen Needle, Diabetic, Safety | 24 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 23 | suppressed |
| Clotrimazole | Clotrimazole | 23 | 12 |
| Anastrozole | Anastrozole | 22 | suppressed |
| Budesonide | Budesonide | 22 | suppressed |
| Calcium Acetate | Calcium Acetate | 22 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Glyburide | Glyburide | 22 | suppressed |
| Jublia | Efinaconazole | 22 | suppressed |
| Trulance | Plecanatide | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 12 |
| Nitroglycerin | Nitroglycerin | 21 | 13 |
| Prednisolone Acetate | Prednisolone Acetate | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Timolol Maleate | Timolol Maleate | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 20 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Meloxicam | Meloxicam | 20 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 14 |
| Invega Sustenna | Paliperidone Palmitate | 19 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 19 | suppressed |
| Oxiconazole Nitrate | Oxiconazole Nitrate | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 18 | suppressed |
| Humalog | Insulin Lispro | 18 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 18 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 15 |
| Benicar | Olmesartan Medoxomil | 17 | suppressed |
| Brilinta | Ticagrelor | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Lubiprostone | Lubiprostone | 17 | suppressed |
| Meloxicam | Meloxicam, Submicronized | 17 | suppressed |
| Meropenem | Meropenem | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Alogliptin | Alogliptin Benzoate | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Glumetza | Metformin Hcl | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Lyrica | Pregabalin | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 16 | suppressed |
| Repaglinide | Repaglinide | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| V-Go 40 | Sub-Q Insulin Device, 40 Unit | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Crestor | Rosuvastatin Calcium | 15 | suppressed |
| Movantik | Naloxegol Oxalate | 15 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | 13 |
| Armour Thyroid | Thyroid,pork | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Dorzolamide-Timolol | Dorzolamide/Timolol/Pf | 14 | suppressed |
| Imatinib Mesylate | Imatinib Mesylate | 14 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 13 | suppressed |
| Exemestane | Exemestane | 13 | suppressed |
| Famciclovir | Famciclovir | 13 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Tobradex | Tobramycin/Dexamethasone | 13 | suppressed |
| Tobramycin | Tobramycin | 13 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 12 | suppressed |
| Dexamethasone | Dexamethasone | 12 | suppressed |
| Ertapenem | Ertapenem Sodium | 12 | suppressed |
| Humalog Mix 50-50 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Opzelura | Ruxolitinib Phosphate | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Proctozone-Hc | Hydrocortisone | 12 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Tavaborole | Tavaborole | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Victoza 3-Pak | Liraglutide | 12 | suppressed |
| Ambien | Zolpidem Tartrate | 11 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Ciclopirox | Ciclopirox | 11 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 11 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Livalo | Pitavastatin Calcium | 11 | suppressed |
| Oxycontin | Oxycodone Hcl | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 11 | suppressed |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 11 | 11 |
| Steglatro | Ertugliflozin Pidolate | 11 | suppressed |
| Tirosint | Levothyroxine Sodium | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $978.17 · 38 records | Novo Nordisk Inc | AVEIR, CAPLYTA, IBSRELA, JARDIANCE, Kerendia, Korlym, MOUNJARO, OTEZLA, Ozempic, REPATHA, Rybelsus, UBRELVY, Veozah, XIFAXAN, ZENPEP, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error